Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France).
Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.
Professor Mohty’s is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.
He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.
Professor Mohty is currently president of the European Society for Blood and Marrow Transplantation (EBMT). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT.
Professor Mohty has published more than 430 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals.
He also serves as Editor-in-Chief of the journal Bone Marrow Transplantation, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as Blood, The Lancet, and Nature Reviews.
Professor Arnon Nagler, MD, MSc Chaim Sheba Medical Center, Israel
Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
Chair of the Acute Leukemia Working Party (ALWP) of the EBMT
Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Thierry FACON, MD Lille University Hospital, Lille, France
Thierry Facon, MD, is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. Professor Facon received his MD at Lille University School of Medicine in 1987 and became Assistant Professor of Haematology at Lille University Hospital in 1989.
Professor Facon was President of the Intergroupe Francophone du Myélome (IFM) between 2003 and 2006, Vice-President of the French Society of Haematology between 2005 and 2013. Professor Facon has presented at several international congresses, including the Plenary session at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2006, the Plenary sessions at the annual meeting of the American Society of Hematology (ASH) in 2013 and 2018 the Educational Session of European Haematology Association (EHA) in 2008 and 2014, and the Educational session of ASH in 2015 and 2018. He co-organized the XIIIth International Myeloma Workshop (IMW) in Paris in 2011, and is a member of the American Society of Hematology (ASH), the International Myeloma Working Group (IMWG), the International Myeloma Foundation (IMF). He is a founder member and administrator of the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) under the aegis of the Fondation de France whose main objective is to enable scientists and students to carry out research programs in host laboratories in France or abroad.
He has presented the “Pierre Stryckmans Memorial Lecture” of the Belgian Hematological Society in 2015 and received the Joseph Michaeli Award from Weill Cornell Medicine, New York USA for his contributions to the treatment of Myeloma Research in 2017 and the International Myeloma Foundation Robert A. Kyle Life Time Achievement Award in 2020. He is an Honorary Professor at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, China since 2015. Professor Facon is author and co-author of a number of articles and has published his work in various prestigious international journals including, as first or senior author, The Lancet and The New England Journal of Medicine.
Don't miss IACH webinar on CAR-T Cells in Lymphoma: the latest data
Thursday, May 19, 2022
6:00pm (Paris), 12:00pm (New York), 7:00pm (Jerusalem)
Free Registration here: https://us06web.zoom.us/webinar/register/WN_fptkJQq7Quiz1OFx60eE5A
Join us for TODAY’s webinar on Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk May 17, 7PM (paris) https://us06web.zoom.us/webinar/register/WN_it6BeF6zQZa49qbZHZjpkA
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.